361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
id |
doaj-f73b789c28e84aa895fb38bc8393d2d1 |
---|---|
record_format |
Article |
spelling |
doaj-f73b789c28e84aa895fb38bc8393d2d12020-12-11T10:01:38ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0361361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomesMagnus Jaderberg0Victor Levitsky1Luis Paz-Ares2Lukasz Kuryk3Nicolas Isambert4Susana Cedres5Xavier Serres6Charles Ricordel7Santiago Ponce Aix8Anne-Sophie Moller9Sylvia Vetrhus101Research and Development, Oslo, Norway1Research and Development, Oslo, Norway2Medical Oncology, Sevilla, Spain1Research and Development, Oslo, Norway2Medical Oncology, Sevilla, Spain2Medical Oncology, Sevilla, Spain3Radiology, Barcelona, Spain4Pulmonology, Rennes, France2Medical Oncology, Sevilla, Spain1Research and Development, Oslo, Norway1Research and Development, Oslo, Norway |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Xavier Serres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus |
spellingShingle |
Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Xavier Serres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes Journal for ImmunoTherapy of Cancer |
author_facet |
Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Xavier Serres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus |
author_sort |
Magnus Jaderberg |
title |
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
title_short |
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
title_full |
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
title_fullStr |
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
title_full_unstemmed |
361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
title_sort |
361 a randomised open-label phase i/ii study adding oncos-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2020-11-01 |
work_keys_str_mv |
AT magnusjaderberg 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT victorlevitsky 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT luispazares 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT lukaszkuryk 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT nicolasisambert 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT susanacedres 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT xavierserres 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT charlesricordel 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT santiagoponceaix 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT annesophiemoller 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes AT sylviavetrhus 361arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma12monthanalysisofbiomarkersandclinicaloutcomes |
_version_ |
1724386628771774464 |